Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Treatment discontinuation in chronic myeloid leukemia: When, how, and why?

“…In the current issue of the American Journal of Hematology, Zambrotta and colleagues report the results of the TFR-PRO study that was conducted to estimate the risk of progression to AP/BP disease among patients eligible for TD. 21 A total of 870 patients with CML-CP and a median age of 57 years were eligible for TD and were divided into a discontinuation cohort (n = 505) and a non-discontinuation (reference) cohort (n = 365). Patients were considered eligible for TD if they received ≥4 years of TKI and had ≥18 months of deep molecular response (DMR, defined as BCR::ABL1 ≤ 0.01% IS).…”